Sandoz has strengthened its biosimilar development capability in Slovenia, advancing a technical development centre intended to support future growth in complex biologic medicines.
The Ljubljana investment forms part of the company’s long-term biosimilar strategy and supports development work across drug substance and drug product activity. Sandoz previously set out plans for a state of the art biosimilar technical development centre in Slovenia, with an investment of around $90 million and approximately 200 planned full-time roles.
The facility is intended to support biopharma technical development as demand for biosimilars grows. Biosimilars are highly similar versions of approved biological medicines and require demanding development, analytical comparison, process control, and regulatory evidence. Unlike small molecule generics, they cannot be treated as simple chemical copies. Their production depends on living systems, controlled processes, and extensive characterisation.
The Slovenia centre therefore sits within a more complex manufacturing and development environment than a conventional expansion of laboratory space. Biosimilar developers need expertise in cell line development, upstream processing, downstream purification, formulation, analytical methods, stability, comparability, scale-up, and regulatory submission support. Technical development connects scientific viability with manufacturability, shaping whether a biosimilar can move from pipeline asset to approved medicine at commercial scale.
European pharmaceutical manufacturing is placing renewed emphasis on resilience, regional capability, and the infrastructure needed to support advanced medicines. Eisai’s investment in Hatfield cold chain packaging and supply capability shows how pharmaceutical capacity is no longer defined only by active production. Controlled handling, packaging, temperature management, and validated distribution are also becoming critical parts of the manufacturing system.
Sandoz’s development centre addresses a different part of the chain, but the direction is related. As biologics and biosimilars become more prominent, life sciences manufacturers need deeper technical capability around process development and industrialisation. A successful biosimilar programme depends on repeatability, analytical confidence, and the ability to control variation before it becomes a regulatory or manufacturing problem.
The strategic case for biosimilars is also strengthening. Healthcare systems face rising medicines costs and growing demand for biologic therapies. Biosimilars can increase competition and improve access, but only where development and production capacity are strong enough to bring products to market reliably.
Slovenia has become an important location for Sandoz and its Lek operations. Building biosimilar capability there gives the company a European base for advanced development work while supporting regional employment and technical skills. It also adds to Europe’s life sciences capacity at a point when governments are looking more closely at medicines supply security and vulnerability to external disruption.
The technical development stage is particularly important because biologics manufacturing is sensitive to process change. Small variations in cell culture, purification, formulation, or storage can affect product attributes and require careful assessment. Development teams must create processes that are scientifically robust and suitable for commercial production, while generating the evidence needed for regulatory confidence.
That places heavy demand on skilled scientists, engineers, quality specialists, and manufacturing technologists. Biosimilar capacity is not built only through cleanrooms, laboratories, or stainless steel. It depends on people able to understand the relationship between process parameters, biological systems, analytical data, and regulatory expectations.
The Slovenia development centre gives Sandoz a stronger platform for that work. It also reflects the direction of pharmaceutical manufacturing in Europe: more advanced products, more complex process control, and a tighter connection between development and supply resilience.
